Three- and four-dimensional-quantitative structure activity relationship (3D/4D-qsar) analyses of CYP2C9 inhibitors

Drug Metabolism and Disposition

Volumn 28, Issue 8, 2000, Pages 994-1002

  Ekins, S ^a   Bravi, G ^a   Binkley, S ^a   Gillespie, J S ^a   Ring, B J ^a   Wikel, J H ^a   Wrighton, S A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 CHLORO 1,2,3,4,4A,5,6,10B OCTAHYDRO 4 METHYLBENZO[F]QUINOLIN 3(2H) ONE; 9 [(DIMETHYLAMINO)METHYL] 6,7,10,11 TETRAHYDRO 9H,18H 5,21; CLOZAPINE; CYTOCHROME P450 2C9; CYTOCHROME P450 INHIBITOR; DICLOFENAC; LY 156735; LY 213829; PHENYTOIN; PIROXICAM; RUBOXISTAURIN; TALAMPANEL; TOLBUTAMIDE; UNCLASSIFIED DRUG; WARFARIN; ZOSUQUIDAR;

ARTICLE; BINDING COMPETITION; CATALYST; COMPETITIVE INHIBITION; HUMAN; HUMAN TISSUE; MODEL; PHARMACOPHORE; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARYL HYDROCARBON HYDROXYLASES; CATALYSIS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; LIVER; MODELS, MOLECULAR; PHENOLS; PROTEIN CONFORMATION; QUINOLONES; REPRODUCIBILITY OF RESULTS; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; THIAZOLIDINES;

EID: 0033856020     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Generating optimal linear PLS estimations (GOLPE): An advanced chemometric tool for handling 3D-QSAR problems
2. MS-WHIM, new 3D theoretical descriptors derived from molecular surface properties: A comparative 3D QSAR study in a series of steroids
3. Application of MS-WHIM descriptors 1. Introduction of new molecular surface properties, and 2. Prediction of binding affinity data
4. Application of MS-WHIM Descriptors 3. Prediction of molecular properties
5. The developing practice of CoMFA, in 3D-QSAR in Drug Design: Theory, Methods and Applications
6. Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19
7. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors
8. Three- and four- dimensional-quantitative structure activity relationship analyses of CYP3A4 inhibitors
9. Three dimensional-quantitative structure activity relationship (3D- QSAR) analyses of substrates for CYP2B6
10. Three-dimensional-quantitative structure activity relationship analyses of CYP3A4 substrates
11. Autoactivation and activation of the cytochrome P450s
12. Structure and function of cytochrome P-450
13. Enzymatic determinants of the substrate specificity of CYP2C9: Role of B'-C loop residues in providing the π-stacking anchor site for warfarin binding
14. Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes
15. Putative active site model for CYP2C9 (tolbutamide hydroxylase)
16. Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase)
17. Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9
18. Pharmacological activity and membrane interactions of antiarrhythmics: 4D-QSAR/QSPR analysis
19. Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen
20. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms
21. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: Evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites
22. QSAR and 3D QSAR in drug design Part 2: Applications and problems
23. Cytochrome P450TB (CYP2C): A major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver
24. Molecular modelling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19; Rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C subfamily
25. The substrate binding site of human liver cytochrome P4502C9: An approach using designed tienilic acid derivatives and molecular modeling
26. Cytochrome P4502C9: An enzyme of major importance in human drag metabolism
27. Tolbutamide hydroxylation by human liver microsomes. Kinetic characterization and relationship to other cytochrome P-450 dependent xenobiotic oxidations
28. Ipriflavone as an inhibitor of human cytochrome P450 enzymes
29. Role of hydrogen-bonding in substrate stracture-activity relationships for CYP2C9
30. Metabolism of non-steroidal anti-inflammatory drugs by cytochrome P450 2C
31. The substrate binding site of human liver cytochrome P4502C9: An NMR study
32. Structure-activity relationships and molecuar modelling studies of a series of Hi antihistamines, in QSAR and Molecular Modelling: Concepts, Computational Tools and Biological Applications
33. Effect of fluoxetine, norfluoxetine, sertraline and desmethyl sertraline on on human CYP3A catalyzed-hydroxy midazolam
34. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A
35. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: Studies of phenytoin phydroxylation
36. Properties of cytochrome P450 isoenzymes and their substrates. Part 1: Active site characteristics
37. Properties of cytochrome P450 isoenzymes and their substrates. Part 2: Properties of cytochrome P450 substrates
38. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes
39. Involvement of multiple cytochrome P450 isoforms in naproxen O- demethylation
40. Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P450-reductase from rabbit liver microsomes
41. SMILES I.Introduction and encoding rules
42. PLS-Partial least squares projections to latent structures
43. Warfarin analog inhibition of human CYP2C9-catalyzed S-warfarin 7- hydroxylation